ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
+3.91%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$173M
AUM Growth
+$173M
(+35%)
Cap. Flow
+$50.2M
Cap. Flow
% of AUM
29.02%
Top 10 Holdings %
Top 10 Hldgs %
55.17%
Holding
85
New
16
Increased
13
Reduced
5
Closed
14
Top Buys
| 1 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$9.1M |
| 2 |
Structure Therapeutics
GPCR
|
$7.82M |
| 3 |
Biohaven
BHVN
|
$7.46M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$6.4M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$5.75M |
Top Sells
Sector Composition
| 1 | Healthcare | 97.66% |
| 2 | Consumer Staples | 0.35% |
| 3 | Communication Services | 0.3% |
| 4 | Materials | 0.17% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
1
DELISTED
Cymabay Therapeutics
CBAY
| $11.9M | 6.22% | 800,000 +131,298 | +20% | +$1.96M |
|
|
IMGN
2
DELISTED
Immunogen Inc
IMGN
| $11.5M | 6% | 725,000 +240,000 | +49% | +$3.81M |
|
3
Astria Therapeutics
ATXS
$349M
| $10M | 5.24% | 1,347,088 | – | – |
|
4
Xtant Medical Holdings
XTNT
$83.3M
| $9.83M | 5.13% | 8,934,362 +2,706,803 | +43% | +$2.98M |
|
|
5
Amylyx Pharmaceuticals
AMLX
$836M
| $9.79M | 5.11% | 534,700 +349,700 | +189% | +$6.4M |
|
6
ADMA Biologics
ADMA
$4.12B
| $9.75M | 5.08% | 2,723,011 +343,011 | +14% | +$1.23M |
|
|
ALIM
7
DELISTED
Alimera Sciences, Inc.
ALIM
| $9.1M | 4.74% | +2,934,108 | New | +$9.1M |
|
|
8
Structure Therapeutics
GPCR
$1.11B
| $7.82M | 4.08% | +155,000 | New | +$7.82M |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $7.79M | 4.06% | 262,000 +127,000 | +94% | +$3.78M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $7.79M | 4.06% | 228,000 | – | – |
|
|
11
Biohaven
BHVN
$1.63B
| $7.46M | 3.89% | +287,000 | New | +$7.46M |
|
12
Axsome Therapeutics
AXSM
$6.05B
| $6.43M | 3.35% | 92,000 +52,000 | +130% | +$3.63M |
|
|
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.75M | 3% | +34,000 | New | +$5.75M |
|
14
MoonLake Immunotherapeutics
MLTX
$3.54B
| $5.02M | 2.62% | 88,000 | – | – |
|
15
Vera Therapeutics
VERA
$1.38B
| $4.57M | 2.39% | 333,681 +213,681 | +178% | +$2.93M |
|
16
Sagimet Biosciences
SGMT
$244M
| $4.25M | 2.22% | +483,181 | New | +$4.25M |
|
17
Olema Pharmaceuticals
OLMA
$375M
| $4.14M | 2.16% | 335,000 +25,000 | +8% | +$309K |
|
18
Harmony Biosciences
HRMY
$2.12B
| $3.83M | 2% | 117,000 -32,889 | -22% | -$1.08M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $3.55M | 1.85% | 29,300 +1,300 | +5% | +$158K |
|
20
Dyne Therapeutics
DYN
$1.92B
| $2.82M | 1.47% | 315,000 +160,000 | +103% | +$1.43M |
|
21
Aclaris Therapeutics
ACRS
$209M
| $2.76M | 1.44% | +403,000 | New | +$2.76M |
|
22
Acumen Pharmaceuticals
ABOS
$82.4M
| $2.7M | 1.41% | +650,000 | New | +$2.7M |
|
23
Replimune Group
REPL
$422M
| $2.65M | 1.38% | 155,000 +25,000 | +19% | +$428K |
|
24
Oric Pharmaceuticals
ORIC
$994M
| $2.53M | 1.32% | +418,706 | New | +$2.53M |
|
25
Cogent Biosciences
COGT
$1.69B
| $2.29M | 1.19% | 235,000 | – | – |
|